<DOC>
	<DOCNO>NCT01214733</DOCNO>
	<brief_summary>This open-label study evaluate long-term safety efficacy RoActemra/Actemra ( tocilizumab ) combination disease modify anti-rheumatic drug ( DMARDs ) patient moderate severe rheumatoid arthritis . Patients successfully complete study WA17823 WA18696 South Africa eligible participate study . Patients allow DMARDs accord treatment receive previous study . Patients receive 8 mg/kg RoActemra/Actemra intravenously every 4 week . The anticipated time study treatment 104 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Plus DMARDs Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Moderate severe rheumatoid arthritis 6 month duration upon enter study Patients successfully complete study WA17823 WA18696 South Africa Body weight &lt; 150 kg Patients withdraw study WA17823 WA18696 eligible participate study Treatment investigational agent since last administration study drug study WA17823 WA18696 Previous treatment cell deplete therapy Treatment intravenous gamma globulin , plasmapheresis Prosorba ( TM ) column since last administration study drug study WA17823 WA18696</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>